Scarica l'app Stockscreener
5.58
3.46%
-0.20
Dopo l'orario di chiusura:
5.61
0.03
+0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - TradingView
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada
Altimmune, Inc. SEC 10-Q Report - TradingView
Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus
Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha
ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia
Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Repor - GuruFocus
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Altimmune Q1 2025 Earnings Call Transcript - MarketBeat
Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus
Altimmune secures $100 million credit facility for drug development - Investing.com
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital - marketscreener.com
Altimmune Q1 Net Income USD -19.575 Million - marketscreener.com
Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus
Altimmune (ALT) Anticipates Q1 Earnings with Positive EPS Revisi - GuruFocus
Altimmune secures $100 million credit facility for drug development By Investing.com - Investing.com India
Altimmune Announces First Quarter 2025 Financial Results and Business Update - The Manila Times
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - The Manila Times
What to Expect from Altimmune's Earnings - Nasdaq
Stifel maintains Buy on Altimmune stock with $18 target By Investing.com - Investing.com UK
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune's (ALT) Pemvidutide Shows Promising Results in Liver Health Study | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - The Manila Times
Altimmune Presents Promising Analyses of Pemvidutide's Efficacy in MASH Treatment at EASL 2025 - Nasdaq
Altimmune at The Citizens JMP Life Sciences Conference: Pembidutide’s Promise - Investing.com
Altimmune to Report First Quarter 2025 Financial Results and Pro - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | ALT Stock News - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - The Manila Times
Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Clinical-Stage Biotech Altimmune Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Trend Tracker for (ALT) - news.stocktradersdaily.com
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
What's Going On With Altimmune (ALT) Stock Today? - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):